Nuvation Bio (NUVB) Common Equity (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Common Equity of $319.6 million for Q1 2026, down 23.82% year-over-year from $419.5 million in Q1 2025, and up 4.53% quarter-over-quarter from $305.7 million in Q4 2025.
Nuvation Bio (NUVB) Common Equity (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Common Equity for 7 consecutive years, with $319.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 23.82% year-over-year to $319.6 million; the TTM figure through Mar 2026 stood at $319.6 million (down 23.82% YoY), while the FY2025 annual figure was $305.7 million, down 34.08% from the prior year.
- Common Equity advanced to $319.6 million in Q1 2026 per NUVB's latest filing, from $305.7 million in the prior quarter.
- Across five years, Common Equity topped out at $723.6 million in Q1 2022 and bottomed at $257.2 million in Q2 2024.
- Historically, Common Equity has averaged $516.7 million across 5 years, with a median of $594.0 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity plunged 58.82% — and 2025, when it surged 44.99%.
- Nuvation Bio's Common Equity stood at $655.1 million in 2022, then dropped by 7.63% to $605.1 million in 2023, then retreated by 23.36% to $463.8 million in 2024, then sank by 34.08% to $305.7 million in 2025, then gained by 4.53% to $319.6 million in 2026.
- Business Quant data shows NUVB's Common Equity at $319.6 million in Q1 2026, $305.7 million in Q4 2025, and $325.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 253.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.86 Mn |
| Mar 31, 2026 | 319.56 Mn |
| Dec 31, 2025 | 305.72 Mn |
| Sep 30, 2025 | 325.88 Mn |
| Jun 30, 2025 | 372.91 Mn |
| Mar 31, 2025 | 419.46 Mn |
| Dec 31, 2024 | 463.79 Mn |
| Sep 30, 2024 | 502.71 Mn |
| Jun 30, 2024 | 257.19 Mn |
| Mar 31, 2024 | 594.04 Mn |
| Dec 31, 2023 | 605.12 Mn |
| Sep 30, 2023 | 611.59 Mn |
| Jun 30, 2023 | 624.63 Mn |
| Mar 31, 2023 | 641.07 Mn |
| Dec 31, 2022 | 655.08 Mn |
| Sep 30, 2022 | 667.94 Mn |
| Jun 30, 2022 | 693.08 Mn |
| Mar 31, 2022 | 723.56 Mn |
| Dec 31, 2021 | 746.00 Mn |
| Sep 30, 2021 | 769.37 Mn |